A drug first designed to prevent cancer cells from multiplying has a second effect: it switches immune cells that turn down the body's attack on tumours back into the kind that amplify it. This is the finding of a study led by researchers from NYU...
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2kiVrnw
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Introduction. Congenital Palmaris Longus (PL) absence was found in 15%–20.25% of population globally. This condition and Flexor Digitorum Su...
-
Ankylosing spondylitis (AS) is a systemic autoimmune disease mainly affecting the lumbar spine and sacroiliac joints, and exhibits periphera...
-
Abstract An electrochemical DNA biosensor based on a G-quadruplex (G4) for the sensitive determination of Pb 2+ was reported using a carb...
-
A drug first designed to prevent cancer cells from multiplying has a second effect: it switches immune cells that turn down the body's a...
-
The majority of hematologist-oncologists who use the social media platform Twitter had some financial conflict of interest, according to new...
-
Contact Dermatitis Early View Online Version of Record before inclusion in an issue ORIGINAL ARTICLESAllergic... Contact Dermatitis Early V...
-
Governments of all political persuasions over the past 20 years have made bold promises to reform the way social care is funded. All have di...
-
In the Original Investigation titled “Yield Strength Testing in Human Cadaver Nasal Septal Cartilage and L-Strut Constructs,” published in t...
-
The present study evaluated the anti-inflammatory and analgesic effects of the superoxide dismutase mimetic agent tempol in superoxide anion...
-
Proton therapy for head and neck cancer: expanding the therapeutic window. Lancet Oncol. 2017 Apr 26;: Authors: Leeman JE, Romesser P...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου